Tiziana Life Sciences Ltd (TLSA)

GB — Healthcare Sector
Peers: ZNTL  SRZN  COYA  ENTX  ARMP  IRD  ONCY  IMDX  OVID  CNTX 

Automate Your Wheel Strategy on TLSA

With Tiblio's Option Bot, you can configure your own wheel strategy including TLSA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol TLSA
  • Rev/Share 0.0
  • Book/Share 0.0721
  • PB 25.5044
  • Debt/Equity 0.0269
  • CurrentRatio 1.0218
  • ROIC -3.5556

 

  • MktCap 102545960.0
  • FreeCF/Share -0.0227
  • PFCF -82.8253
  • PE -6.0777
  • Debt/Assets 0.0094
  • DivYield 0
  • ROE -5.7044

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program
TLSA
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the dosing of an additional four patients in its Intermediate Size Patient Population Expanded Access (ISPPEA) for patients with non-active secondary progressive multiple sclerosis (na-SPMS) who do not qualify for the ongoing Phase 2a study (NCT06292923).

Read More
image for news Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program
Tiziana Life Sciences says foralumab shows promise in Alzheimer's treatment
TLSA
Published: February 11, 2025 by: Proactive Investors
Sentiment: Positive

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said its investigational drug, intranasal foralumab, is gaining attention for its potential to address Alzheimer's disease, a condition with limited treatment options. The company's expanded access program for moderate Alzheimer's has allowed the first patient to receive the therapy, offering hope for those battling the disease.

Read More
image for news Tiziana Life Sciences says foralumab shows promise in Alzheimer's treatment

About Tiziana Life Sciences Ltd (TLSA)

  • IPO Date 2018-11-20
  • Website https://www.tizianalifesciences.com
  • Industry Biotechnology
  • CEO Ivor R. Elrifi
  • Employees 9
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.